A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer

Abstract

Anlotinib monotherapy or combination therapy provide a viable third-line or above therapeutic strategy in patients with HER-2 negative metastatic breast cancer, a median PFS of 5.0 months was obtained with well tolerated toxicity.